Socioeconomic status (SES) has an impact on prostate cancer (PCa) outcomes. Men with high SES have higher incidence and lower mortality of PCa versus lower SES males. PCa cases diagnosed in Finland in 1985-2014 (N 5 95,076) were identified from the Finnish Cancer Registry. Information on education level (EL) was obtained from Statistics Finland. EL was assessed with three-tiered scale: basic, upper secondary and higher education. PCa stage at diagnosis was defined as localized, metastatic or unknown. Years of diagnosis 1985-1994 were defined as pre-PSA period and thereafter as post-PSA period. We report PCa-specific survival (PCSS) and relative risks (RR) for PCa specific mortality (PCSM) among cancer cases in Finland, where healthcare is 100% publicly reimbursed and inequality in healthcare services low. Men with higher EL had markedly better 10-year PCSS: 68 versus 63% in 1985-1994 and 90 versus 85% in 1995-2004 compared to basic EL in localized PCa. The RR for PCSM among men with localized PCa and higher EL compared to basic EL was 0.76(95%confidence interval (CI) 0.66-0.88) in 1985 -1994 and 0.61(95%CI 0.53-0.70) in 1995 -2004 . Variation in PCSS and PCSM between EL categories was evident in metastatic PCa, too. The difference in PCSM between EL categories was larger in the first 10-year post-PSA period than before that but decreased thereafter in localized PCa, suggesting PSA testing became earlier popular among men with high EL. In summary, higher SES/EL benefit PCa survival both in local and disseminated disease and the effect of EL was more pronounced in early post-PSA period.
Lower socioeconomic status (SES) in terms of shorter education is associated with higher prevalence of obesity, type 2 diabetes and metabolic syndrome. 1 Furthermore, these comorbidity-related factors correlate with higher cancer stage and delayed prostate cancer (PCa) diagnosis. 2 SES indicators mean various factors such as education level (EL), income and occupation. 3 Nonetheless, information on underlying causes that explain socioeconomic differences in PCa survival is sparse. 4 Higher incidence of PCa is described among men with higher SES in developed countries like Finland [5] [6] [7] while men with lower SES have higher PCa mortality. 8 The increased PCa mortality among lower SES groups have been explained by higher tumor aggressiveness, comorbidities, treatment choices and metabolic indicators. 9 Men with lower SES tend to have higher disease stage at the time of diagnosis and are consequently less likely to undergo curative treatment and more likely treated with watchful waiting. 8, 10 Furthermore, palliative methods such as androgen deprivation therapy are more common in lower SES groups, even in localized disease.
screening arm and men with lower SES had more advanced disease stage compared to those with higher SES. 16 The possible impact of social inequality in PCa survival and the difference on PCa treatment or detection is important to investigate. We evaluated whether SES defined, as educational length was associated with PCa outcome. The aim of this study was to assess the possible inequality of different SES groups in terms of PCa-specific survival (PCSS) and mortality (PCSM) as well as mortality due to causes other than PCa among patients diagnosed before and after the advent of PSA testing in a setting of a 100% reimbursed public health care system.
Material and Methods

Study population
The nationwide population-based Finnish Cancer Registry (FCR) collects information on incident cancers annually from hospitals, outpatient clinics and other healthcare facilities and separately from histopathological laboratories in Finland. 17 Additionally, all deaths of cancer patients and death certificates where cancer is mentioned are reported to the registry by Statistics Finland.
The study cohort was chosen from year 1985 to cover cases diagnosed before and after the introduction of PSA testing that became popular in Nordic countries in the late 1990s. 18 Moreover, result from Finnish Randomized Study of Screening for Prostate Cancer showed that only 1.4% of men either in the screening arm or in the control arm had undergone PSA testing 1-3 years prior randomization in 1997-1999. 19 This emphasizes that PSA testing was uncommon in
Finland prior year 1995. Furthermore, that particular study covered men from two largest Finnish metropolitan areas: Helsinki and Tampere, where assumingly PSA testing was more common than in rural area. Thus, the years from 1995 were described as post-PSA period and years before 1995 as pre-PSA period. PCa cases diagnosed from 1985 until December 31, 2014 were retrieved from the FCR and were followed-up to the end of 2014 for deaths from PCa. Cases were defined as localized or metastatic at diagnosis based on the classification at the FCR. Definition of metastases was mostly done with bone scan examination. 20 SES groups were identified from Statistics Finland. Division between SES groups was based on EL using the most recent antecedent information from census, the ELs were divided into three categories according to the highest attained educational degree or certificate as follows: basic (lasting typically <10 years), upper secondary (10-12 years) and higher education (13 years or more). The study protocol was approved by the IRB of the Southwestern hospital district of Finland. The Finnish National Institute of Health and Welfare approved access to registry data (study number 182/5.05.00/2015). Statistics Finland approved access to cause of death and SES data (study number TK-53-86-17).
Statistical analysis
Cumulative cause-specific survival with respect to deaths from PCa (PCSS) was estimated by EL, calendar period of diagnosis (1985-1994, 1995-2004 and 2005-2014) and tumor spreading (localized, metastatic and unknown) by using a life table method. 21 Traditional direct age standardization was used for survival comparisons between the ELs and the calendar periods as the groups differed in age structures. 22 The age distribution of the patients diagnosed in the whole study period 1985-2014 by tumor stage was used as the standard (five age groups: 0-54, 55-64, 65-74, 75-84 and 85 years old and older). Poisson regression model was used to quantify differences in patients' mortality between ELs. The model results are reported as relative risks (RR) for PCa mortality and mortality from causes other than PCa. The models included 6 follow-up time intervals (annual intervals from 0 to 5 years and a 5-year interval 5-10 years), age at diagnosis (the same categories as in the age standardization), and the level of education. The models were fitted separately for each period and stage. Interactions between age and follow-up time, and age and EL were included to allow for non-proportional PCa mortality by these variables. 23 The models were compared with the simpler models where the effect of education is the same across age groups. Higher education level can help a man fight off prostate cancer, according to this report from Finland. These authors tested the association between high socioeconomic status and prostate cancer incidence and survival. Men with high status, as delineated by education level had higher incidence of prostate cancer. However, men with lower socioeconomic status tended to get diagnosed when the cancer was already at a more advanced stage, and had higher mortality than men of higher status. These data show the need for more education and screening for people of lower socioeconomic status, to avert preventable deaths.
between consecutive periods (p C ) were based on the likelihood ratio test. The first 10 years of follow-up was considered and longer survival times were censored at 10 years.
Results
Half of the identified PCa patients had localized disease (N 5 49,047, 51.6%) and one fifth had metastatic disease (N 5 18,325, 19.3%). The vast majority (66%) of the whole study population were old (>70 years) at diagnosis. The stage remained unknown in close to one third of patients (N 5 27,704, 29.1%) overall and missing stage increased over time (Table 1) .
Survival analysis
Men in higher and upper secondary EL with localized PCa had better 10-year PCSS than men in basic EL in 1985-1994 ( Fig. 1 and Table 2 ). In 1995-2004 men in higher EL had distinctly better 10-year PCSS than other groups ( Men in higher EL with metastatic disease had better PCSS than men in basic EL during the study period. In 1985-1994, 10-year PCSS was 13% (basic EL), 14% (upper secondary EL) and 17% (higher EL). In 1995-2004, 10-year PCSS was 31% (basic EL), 35% (upper secondary EL) and 38% (higher EL), respectively. Survival increased clearly from the pre-to the post-PSA period in all EL groups ( Fig. 2 and Table 2 ).
Among men with unknown PCa stage, 10 years PCSS was better in higher EL than lower levels and improved from the pre-to the post-PSA period (Table 2) .
Mortality from prostate cancer and other causes
In men with localized PCa in the first period (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) : RR for PCSM was 0.76 (95% CI 0.66-0.88) in higher EL and 0.81 (95% CI 0.69-0.95) in upper secondary EL, compared to those in basic EL, respectively (Table 3 ). In 1994-2004, the RRs were 0.61 (95%CI 0.53-0.70) in higher EL and 0.84 (95%CI 0.73-0.96) in upper secondary EL, respectively ( Table  3 ). The clear differences between EL groups, however, disappeared in the latter post-PSA period 2005-2014 (p 5 0.293 for heterogeneity) and RR was 0.87 (95%CI 0.72-1.04) in higher and 0.94 (0.78-1.14) in upper secondary EL (Table 3) .
Risk of dying from PCa was lower for men in higher EL compared to basic EL also in metastatic disease and the difference stayed during the whole study period: RR was 0. (Table 3) .
Relative risk for mortality from other causes than PCa was 0.71 (95% CI 0.64-0.80), 0.69 (95% CI 0.64-0.74) and 0.65 (95% CI 0.59-0.71) in 1985-1994, 1995-2004 and 2005-2014 
Discussion
In this population-based study on PCa patients in Finland, we found that PCSS was lower in men with lower SES (defined as EL) compared to men with high SES. . Risk for PCa death was lower among men with high SES also in metastatic disease during the past 30 years and this difference was seen also in recent years. Mortality from causes other than PCa was considerably lower for men in high EL during the whole study period in all disease stage groups (all p < 0.005 for heterogeneity in mortality within each period).
The overall incidence of PCa increased dramatically over time in the post-PSA period. This trend was most obvious in localized PCa, especially among men with higher EL. Furthermore, in post-PSA period, more cases were diagnosed in younger men. This reflects an increased interest to PSA testing among younger (<70 years of old) well-educated men. 12, 13 However, the FCR data contained higher proportion of unknown PCa stage cases in recent years. Group with unknown stage may mostly contain men with localized PCa since the better PCSS for men in higher SES was most clearly seen in this stage group. In localized cancer, the PCa survival remained at the same level from 1995-2004 to 2005-2014 in men with high education whereas it increased in lower education groups, and in the latter post-PSA period 2005-2014, the differences between ELs disappeared. The large p values (for heterogeneity in PCa mortality across ELs) in the last period may also be related to the sparseness of data. However, a clear change in the RRs between the two last periods was observed (p 5 0.01), and also the differences between the point estimates of RRs in 1995-2004 were smaller than those in 2005-2014. A possible explanation is that PSA testing among men with low education became widely common not until the latter post-PSA period, later than among men with high education. While we consider that this diminishing difference between groups is partly due to increased uptake of
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Seikkula et al. PSA screening, it has been demonstrated that recent recommendations to reduce PSA screening in US has led to increase in PCa distant metastases. 24 However, the difference between SES groups was not investigated in that report.
Men with higher EL had lower mortality from causes other than PCa compared to men with lower EL during the whole study period in all stage groups. This might mean that men in higher EL are more health conscious and have better 4 Threefold number (from earliest to latest cohort) of metastatic PCa was found on men with higher EL compared to only 1.5 fold in basic EL. Intensive screening and diagnostic procedures of men with higher education background probably explain this trend. Thus, for example, cases with oligometastatic/low metastatic tumor burden are discovered earlier than those in men with low education. When metastatic disease was detected, there probably was no inequality to have treatment for metastatic PCa. Interestingly, the proportion of men with basic EL was high during the period of observation. Most men who were diagnosed with PCa in pre-PSA period and in early post-PSA period were born in 1910s and 1920s, when the opportunity to get higher education was more limited. Thus, EL probably does not define SES among older males as well as it does among younger ones. Other variables than EL, such as incomes, should also be balanced when the effect of SES on PCa outcome is described. According to recent population based study from United States both higher education and higher incomes were independent indicators for better PCa survival. 25 Also Aarts et al. reported two different studies from Netherlands that high education correlates with distinctly higher survival of PCa whereas income rate showed clear but smaller difference in survival of PCa. Nonetheless, it was evident that patients with higher taxable incomes received more often radical treatments and were younger at the time of diagnosis than men with smaller incomes. 26, 27 Our findings from FCR cohort showed clear discrepancies between different educational SES groups on PCa survival in Finland and the significant differences were seen in all cancer stages. Several previous reports have showed similar results. 8, 28, 29 Earlier Finnish report stated that, in 1996-2005, 20-25% of deaths from PCa could have been avoided in the first 10 years after diagnosis if all patients had the same PCa survival as that in the higher EL. 30 The increased mortality is largely attributable to delayed diagnosis, suboptimal diagnostic workup, and less invasive treatments among these individuals. 8 Similar results have been reported also with other malignancies, such as colon and breast, etc. 31, 32 Large Swedish populationbased study on high-risk PCa patients showed that blue-collar workers were less likely to be treated with RP than patients in white-collar occupation. 28 Earlier English study showed that patients with lower SES were rarely treated with radical surgery or radiotherapy but more common with watchful waiting. 10 Furthermore, men in lower SES are more often treated with observation or hormonal therapy than those in higher SES. 4 The reason to offer less intensive treatments for men in lower SES may be due to comorbid conditions. Men in lower SES are in higher risk to die from cardiovascular diseases than those in higher SES. 33 However, the association of potential mediating factors is unclear. Recent Danish cohort study of PCa patients showed that men in lower SES status were often overweight and obese at baseline, and increased cancer-specific and allcause mortality can also be explained by lifestyle and comorbidity factors. 9 We conducted this Finnish study of PCa outcomes during pre-and post-PSA era. While the number of newly diagnosed PCa cases increased among men with higher education level during post-PSA period, these men were probably more fit and health conscious and prone to undergo screening procedures. Wide utilization of PSA testing typically results in overdiagnosis and causes lead-time bias in survival estimates. Lead-time, the time by which PSA screening advances prostate cancer diagnosis, has been reported by several studies, with mean lead times ranging from 3 to 12 years. 34 Most probably this bias can also been seen in these survival estimates. Thus, lead-time issues can partly explain better survival of men with higher EL in post-PSA period. Also other variables such as radical treatments assumingly explain the differences in PCa survival. In the Nordic countries, however, treatment with curative intent, whether RP or radiotherapy was not extensively adopted until the mid-1990. 35 Thus inequality to have radical PCa treatment cannot explain the difference in earlier years of our cohort. This conclusion is probably true also in recent years: according to results from the Scandinavian prostate cancer Group-4 randomized trial, no clear impact of RP on mortality was seen for about 10 yr. 36 There are several strengths in the study. To our knowledge, this is largest study comparing PCSM and PCSS between different EL groups. First, it covers nearly 100% of men who have been diagnosed with PCa during a long period of time. Furthermore, also information about SES contains 100% of the population. The data also covers specific cause of death information of all individuals. Therefore, the difference in PCa survival describes the real relation between SES groups in Finland. This study is not without limitations. We lacked data about more specified cancer information such as Gleason scores and PSA values. One main limitation is high proportion (29%) of patients with unknown cancer stage. Furthermore, we did not evaluate the different cancer treatments. The data from FCR and other registries in Finland is not complete regarding cancer treatments. We also couldn't assess specific comorbidities of the study population. We will later address this issue by collecting more information of medication history, treatments, cancer histology and incomes of these patients.
The seen inequality between men with different education background is, indeed, worrying. Men with lower education are carrying worse prognosis of PCa. It was also apparent that the majority of men with metastatic PCa were at basic EL even in recent years. However, while more and more localized PCa was detected during the study period, many of these cases were detected by PSA screening. Thus, the 
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difference is partly explained with lead-time issues and "the real" cancer survival between SES groups may be less pronounced.
Conclusions
The effect on PSA testing can clearly be seen in our results on PCa survival by SES in Finland during the past 30 years. More healthcare resources should be utilized to prevent and treat comorbidities, offer diagnostics and radical cancer treatments for men with lower SES. The health awareness of citizens with low EL should be improved to avoid unnecessary, preventable, cancer deaths of these individuals. When the PSA testing is common, highly educated men are likely overrepresented in screening population. The possible benefits of testing and screening would only be gained if PSA screening would be provided for all citizens in an organized manner. However, the dilemma of overdiagnostics and overtreatment of PCa still remain.
